RANI vs RAKR: Which is Better to Buy in 2026?

Side-by-side fundamental comparison based on AI analysis of SEC filings

AI Verdict

RANI has stronger fundamentals based on our AI analysis.

RANI
Rani Therapeutics Holdings, Inc.
SELL
48%
Confidence
VS
RAKR
Rainmaker Worldwide Inc.
STRONG SELL
95%
Confidence

RANI vs RAKR Fundamental Comparison

Metric RANI RAKR
Revenue $1.6M $34,250.0
Net Income $-29.7M $-929,521.0
Net Margin -1,817.1% -2,713.9%
ROE -89.9% N/A
ROA -50.6% -892.1%
Current Ratio 4.21x 0.01x
Debt/Equity 0.00x N/A
EPS $-0.45 $-0.02

Green = Better metric | Red = Weaker metric

View Full RANI Analysis →
View Full RAKR Analysis →
Browse Sectors: Technology Healthcare Finance Energy Consumer Industrial
Stock Lists: Strong Buy Undervalued Growth Dividend

You Might Also Compare

RANI vs AAPL RAKR vs MSFT RANI vs GOOGL RAKR vs AMZN

RANI vs RAKR: Frequently Asked Questions

Is RANI or RAKR a better buy in 2026?

Based on dual AI fundamental analysis (Claude and ChatGPT), RANI has stronger fundamentals. RANI is rated SELL (48% confidence) while RAKR is rated STRONG SELL (95% confidence). This is not investment advice.

How does RANI compare to RAKR fundamentally?

Rani Therapeutics Holdings, Inc. has ROE of -89.9% vs Rainmaker Worldwide Inc.'s N/A. Net margins are -1,817.1% vs -2,713.9% respectively.

Which stock pays higher dividends, RANI or RAKR?

RANI has a dividend yield of N/A or no dividend while RAKR has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.

Should I invest in RANI or RAKR for long term?

For long-term investing, consider that RANI has SELL rating with 48% confidence, while RAKR has STRONG SELL rating with 95% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.

What do the AI models say about RANI vs RAKR?

Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RANI vs RAKR, the AI consensus favors RANI based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.